News

According to Korea Biomedical Review (KBR), the company’s flagship autoimmune disease treatment, called ‘Remsima’, has secured a substantial tender from the Peruvian Workers’ Insurance System (EsSalud).  This tender

This partnership will utilise Scenic Biotech’s Cell-Seq platform to identify target biology for indication selection and expansion.  Under the new agreement, Scenic Biotech will receive an upfront payment,

This approval marks a significant milestone as TIVDAK becomes the first antibody-drug conjugate (ADC) with proven overall survival data to receive such endorsement in this patient group. The

RAG-01 is a new therapy aimed at treating non-muscle invasive bladder cancer (NMIBC). This regulatory milestone enables the commencement of clinical trials in the US. NMIBC accounts for

As part of the new collaboration, the two companies will work together to co-create the candidate for the oncology target, leveraging PepMetics technology.  Once the development candidate is

This acceptance will allow GSK to potentially expand the use of Jemperli for the treatment of primary advanced or recurrent endometrial cancer in all the adult patients, including

As part of this strategic partnership, the two companies aim to leverage their shared technology as well as clinical development resources to create synergies in therapeutics development.  The

The deal, valued at up to $380m, includes upfront and milestone payments. Under the terms of the agreement, Cellares will streamline, automate, and transfer technology for selected BMS

Merck, referred as MSD outside the US and Canada, has confirmed that Health Canada has approved a new indication for PREVYMIS (letermovir) to prevent cytomegalovirus (CMV) disease in